ResearcherCharles UniversityActive in the last 2 years
David Větvička
Matched on ORCID iD 0000-0002-6098-1213; OpenAlex author ID A5065387605. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 13
2021: 2 papers · 2022: none · 2023: 1 paper · 2024: 2 papers · 2025: none · 2026: 1 paper
Papers 6
- Opsonization and timing as key determinants of MBTA immunotherapy efficacy in pancreatic adenocarcinoma and recurrence treatment. Co-author DOI 10.1080/15384047.2026.2683273↗
- Temoporfin-Conjugated PEGylated Poly(N,N-dimethylacrylamide)-Coated Upconversion Colloid for NIR-Induced Photodynamic Therapy of Pancreatic Cancer. Co-author DOI 10.1021/acs.biomac.4c00317↗
- Intraperitoneal versus intravenous administration of Flamma®-conjugated PEG-alendronate-coated upconversion nanoparticles in a mouse pancreatic cancer model. Co-author DOI 10.1039/d4na00764f↗
- Temoporfin-Conjugated Upconversion Nanoparticles for NIR-Induced Photodynamic Therapy: Studies with Pancreatic Adenocarcinoma Cells In Vitro and In Vivo. First author DOI 10.3390/pharmaceutics15122694↗
- Gene silencing delivery systems for the treatment of pancreatic cancer: Where and what to target next? Co-author DOI 10.1016/j.jconrel.2021.01.020↗
- Polycation fluorination improves intraperitoneal siRNA delivery in metastatic pancreatic cancer. Co-author DOI 10.1016/j.jconrel.2021.03.028↗
Closest collaborators
The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Oleksandr Shapoval · 3 shared papers, 2023–2024 · strength 0.64
- Paper Intraperitoneal versus intravenous administration of Flamma®-conjugated PEG-alendronate-coated upconversion nanoparticl… DOI 10.1039/d4na00764f↗
- Paper Temoporfin-Conjugated PEGylated Poly(N,N-dimethylacrylamide)-Coated Upconversion Colloid for NIR-Induced Photodynamic T… DOI 10.1021/acs.biomac.4c00317↗
- Paper Temoporfin-Conjugated Upconversion Nanoparticles for NIR-Induced Photodynamic Therapy: Studies with Pancreatic Adenocar… DOI 10.3390/pharmaceutics15122694↗
- Daniel Horák · 3 shared papers, 2023–2024 · strength 0.64
- Paper Intraperitoneal versus intravenous administration of Flamma®-conjugated PEG-alendronate-coated upconversion nanoparticl… DOI 10.1039/d4na00764f↗
- Paper Temoporfin-Conjugated PEGylated Poly(N,N-dimethylacrylamide)-Coated Upconversion Colloid for NIR-Induced Photodynamic T… DOI 10.1021/acs.biomac.4c00317↗
- Paper Temoporfin-Conjugated Upconversion Nanoparticles for NIR-Induced Photodynamic Therapy: Studies with Pancreatic Adenocar… DOI 10.3390/pharmaceutics15122694↗
- Taras Vasylyshyn · 2 shared papers, 2024 · strength 0.45
- Paper Intraperitoneal versus intravenous administration of Flamma®-conjugated PEG-alendronate-coated upconversion nanoparticl… DOI 10.1039/d4na00764f↗
- Paper Temoporfin-Conjugated PEGylated Poly(N,N-dimethylacrylamide)-Coated Upconversion Colloid for NIR-Induced Photodynamic T… DOI 10.1021/acs.biomac.4c00317↗
- Jan Ženka · 1 shared paper, 2026 · strength 0.28
- Andrea Frejlachova · 1 shared paper, 2026 · strength 0.28
- Katerina Hadrava Vanova · 1 shared paper, 2026 · strength 0.28
- Ondřej Uher · 1 shared paper, 2026 · strength 0.28
- Hang Yu · 2 shared papers, 2021 · strength 0.27
- David Oupický · 2 shared papers, 2021 · strength 0.27
- Rubayat Islam Khan · 1 shared paper, 2021 · strength 0.15
- Siyuan Tang · 1 shared paper, 2021 · strength 0.12
- Ying Xie · 1 shared paper, 2021 · strength 0.12
- Rakesh K. Singh · 1 shared paper, 2021 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.